Previous 10 | Next 10 |
home / stock / rmd / rmd articles
The Zacks Medical – Products industry's revenues are expected to continue its growth trajectory on the back of the recovery in demand for...
ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 4.44% on an annualized basis producing an average annual return of 17.24%. ...
Zimmer Biomet (NYSE: ZBH) and RevelAi Health accepted a multi-year co-marketing agreement to commercialize generative artificial intelligence-...
Abbott (NYSE: ABT) announced that Lingo and Libre Rio, two of its glucose monitoring system, have received FDA clearance. Lingo and Libre Rio are b...
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year re...
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 7.11% on an annualized basis producing an average annual return of 15.03%. ...
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio a...
Haemonetics Corporation‘s (NYSE: HAE) shares have increased 10.8% year to date compared with the industry's rise of 6.1%. The Medical sec...
ResMed (NYSE:RMD) has outperformed the market over the past 10 years by 4.86% on an annualized basis producing an average annual return of 15.65%. ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-29 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. He...
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to increase 26.7%...